Browse > Article

Development of a Quantitative ELISA for Anti HER-2 Antibodies using Human HER-2 Recombinant Proteins  

Jung, Sun-Ki (College of Pharmacy and Research Center for Transgenic Cloned Pigs, Chungnam National University)
Ryu, Chang-Seon (College of Pharmacy and Research Center for Transgenic Cloned Pigs, Chungnam National University)
Choung, Kyu-Jin (College of Pharmacy and Research Center for Transgenic Cloned Pigs, Chungnam National University)
Song, Gyu-Yong (College of Pharmacy and Research Center for Transgenic Cloned Pigs, Chungnam National University)
Kim, Sang-Kyum (College of Pharmacy and Research Center for Transgenic Cloned Pigs, Chungnam National University)
Publication Information
YAKHAK HOEJI / v.55, no.1, 2011 , pp. 16-21 More about this Journal
Abstract
HER-2 (Human Epidermal Growth Factor Receptor-2) is a protein giving higher aggressiveness in human breast cancers. Trastuzumab is a monoclonal antibody that targets HER-2 and is known to extend survival across all stages of HER2-positive breast cancer. In this study, we attempted to development of a quantitative ELISA (Enzyme-Linked ImmunoSorbent Assay) for evaluating anti HER-2 antibodies using human HER-2 recombinant proteins to support antibody producing processes and pharmacokinetic studies. We established direct or indirect ELISA method for the trastuzumab-like protein combined human recombinant HER-2. The ELISA method will prove to be great value in quantitating anti-HER-2 antibodies levels for developing anticancer antibodies.
Keywords
ELISA; Trastuzumab; HER-2; breast cancer;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Piechocki, M. P., Pilon, S. A. and Wei, W. Z. : Quantitative measurement of anti-ErbB-2 antibody by flow cytometry and ELISA. J. Immunol. Methods 259, 33 (2002).   DOI
2 Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., Rosen, P. P., Twaddell, T., Henderson, I. C. and Norton, L. : Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 14, 737 (1996).   DOI
3 Pegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly, D., Baughman, S. A., Twaddell, T., Glaspy, J. A. and Slamon, D. J. : Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/ neu monoclonal antibody plus cisplatin in patients with HER2/ neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 16, 2659 (1998).
4 Pegram, M., Hsu, S., Lewis, G., Pietras, R., Beryt, M., Sliwkowski, M., Coombs, D., Baly, D., Kabbinavar, F. and Slamon, D. : Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18, 2241 (1999).   DOI   ScienceOn
5 Leyland-Jones, B., Gelmon, K., Ayoub, J. P., Arnold, A., Verma, S., Dias, R. and Ghahramani, P. : Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J. Clin. Oncol. 21, 3965 (2003).   DOI   ScienceOn
6 Baselga, J., Carbonell, X., Castañeda-Soto, N. J., Clemens, M., Green, M., Harvey, V., Morales, S., Barton, C. and Ghahramani, P. : Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J. Clin. Oncol. 23, 2162 (2005).   DOI   ScienceOn
7 Bruno, R., Washington, C. B., Lu, J. F., Lieberman, G., Banken, L. and Klein, P. : Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol. 56, 361 (2005).   DOI   ScienceOn
8 King, C. R., Kraus, M. H. and Aaronson, S. A. : Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229, 974 (1985).   DOI
9 Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A. and McGuire, W. L. : Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177 (1987).   DOI
10 Di Fiore, P. P., Pierce, J. H., Kraus, M. H., Segatto, O., King, C. R. and Aaronson S. A. : erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237, 178 (1987).   DOI
11 Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G. and Keith, D. E. : Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707 (1989).   DOI
12 Moasser, M. M. : The oncogene HER-2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26, 6469 (2007).   DOI   ScienceOn
13 Press, M. F. and Lenz, H. J. : EGFR, HER-2 and VEGF pathways, validated targets for cancer treatment. Drugs 67, 2045 (2007).   DOI   ScienceOn
14 Hortobagyi, G. N. : Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. Semin Oncol. 28(6 Suppl 18), 43 (2001).   DOI
15 Clynes, R. A., Towers, T. L. and Presta, L. G. : Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6, 443 (2000).   DOI   ScienceOn
16 Maple, L., Lathrop, R., Bozich, S., Harman, W., Tacey, R., Kelley, M. and Danilkovitch-Miagkova, A. : Development and validation of ELISA for Herceptin detection in human serum. J. Immunol. Methods 295, 169 (2004).   DOI   ScienceOn
17 Sias, P. E., Kotts, C. E., Vetterlein, D., Shepard, M. and Wong, W. L. : ELISA for quantitation of the extracellular domain of p185HER2 in biological fluids. J. Immunol. Methods 132, 73 (1990).   DOI   ScienceOn